v3.25.2
Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common stock
Additional paidin capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total
Balance at Beginning of period at Dec. 31, 2023   $ 705,794 $ (43) $ (594,468) $ 111,283
Balance at Beginning of period (in shares) at Dec. 31, 2023 2,805,618        
Balance at end of period at Mar. 31, 2024   716,131 (69) (611,179) 104,883
Balance at end of period (in shares) at Mar. 31, 2024 3,139,002        
Balance at Beginning of period at Dec. 31, 2023   705,794 (43) (594,468) 111,283
Balance at Beginning of period (in shares) at Dec. 31, 2023 2,805,618        
Stockholders' equity          
Issuance of common stock under the ATM Facility, net of offering costs   8,742     8,742
Issuance of common stock under the ATM Facility, net of offering costs (in shares) 300,000        
Exercise of stock options and vesting of restricted stock units   35     35
Exercise of stock options and vesting of restricted stock units (in shares) 35,607        
Issuance of shares in connection with employee stock purchase plan   50     50
Issuance of shares in connection with employee stock purchase plan (in shares) 4,929        
Unrealized gain (loss) on marketable securities     (24)   (24)
Sharebased compensation expense   3,173     3,173
Net loss       (32,702) (32,702)
Balance at end of period at Jun. 30, 2024   717,794 (67) (627,170) 90,557
Balance at end of period (in shares) at Jun. 30, 2024 3,146,154        
Balance at Beginning of period at Mar. 31, 2024   716,131 (69) (611,179) 104,883
Balance at Beginning of period (in shares) at Mar. 31, 2024 3,139,002        
Stockholders' equity          
Exercise of stock options and vesting of restricted stock units   35     35
Exercise of stock options and vesting of restricted stock units (in shares) 2,223        
Issuance of shares in connection with employee stock purchase plan   50     50
Issuance of shares in connection with employee stock purchase plan (in shares) 4,929        
Unrealized gain (loss) on marketable securities     2   2
Sharebased compensation expense   1,578     1,578
Net loss       (15,991) (15,991)
Balance at end of period at Jun. 30, 2024   717,794 (67) (627,170) 90,557
Balance at end of period (in shares) at Jun. 30, 2024 3,146,154        
Balance at Beginning of period at Dec. 31, 2024   720,488 8 (659,235) 61,261
Balance at Beginning of period (in shares) at Dec. 31, 2024 3,161,503        
Stockholders' equity          
Exercise of stock options and vesting of restricted stock units (in shares) 14,325        
Issuance of shares in connection with employee stock purchase plan   14     14
Issuance of shares in connection with employee stock purchase plan (in shares) 2,882        
Unrealized gain (loss) on marketable securities     $ (8)   (8)
Sharebased compensation expense   1,781     1,781
Net loss       (24,790) (24,790)
Balance at end of period at Jun. 30, 2025   722,283   (684,025) 38,258
Balance at end of period (in shares) at Jun. 30, 2025 3,178,710        
Balance at Beginning of period at Mar. 31, 2025   721,346   (674,640) 46,706
Balance at Beginning of period (in shares) at Mar. 31, 2025 3,165,828        
Stockholders' equity          
Exercise of stock options and vesting of restricted stock units (in shares) 10,000        
Issuance of shares in connection with employee stock purchase plan   14     14
Issuance of shares in connection with employee stock purchase plan (in shares) 2,882        
Sharebased compensation expense   923     923
Net loss       (9,385) (9,385)
Balance at end of period at Jun. 30, 2025   $ 722,283   $ (684,025) $ 38,258
Balance at end of period (in shares) at Jun. 30, 2025 3,178,710